Bruce Wang1. 1. Department of Medicine, University of California, San Francisco, San Francisco, California, USA.
Abstract
PURPOSE OF REVIEW: Acute hepatic porphyrias (AHP) are a group of rare diseases that are characterized by episodic acute neurovisceral pain episodes caused by abnormal accumulation of the neurotoxic porphyrin precursor delta-aminolevulinic acid (ALA). Patient with frequent recurrent acute attacks have been difficult to treat and these patients sometimes require liver transplantation. Recent developments in small interfering RNA (siRNA)-based therapy led to the development of an effective prophylactic treatment for patients with frequent recurrent attacks. This review will describe treatment options for AHP and highlight management in light of new treatment option. RECENT FINDINGS: Givosiran is a novel siRNA-based therapy targeted specifically to hepatocytes to inhibit ALA synthase 1, the first and rate-limiting step in heme biosynthesis. Patients with frequent recurrent attacks treated with givosiran had durable normalization of ALA and significantly reduced numbers of acute attacks and need for hemin treatment. The overall safety profile for givosiran was comparable with placebo and the drug was recently approved by the Food and Drug Administration for treatment of AHP patients. SUMMARY: Givosiran is an effective treatment for prevention of acute porphyria attacks in AHP patients with frequent recurrent attacks.
PURPOSE OF REVIEW: Acute hepatic porphyrias (AHP) are a group of rare diseases that are characterized by episodic acute neurovisceral pain episodes caused by abnormal accumulation of the neurotoxic porphyrin precursor delta-aminolevulinic acid (ALA). Patient with frequent recurrent acute attacks have been difficult to treat and these patients sometimes require liver transplantation. Recent developments in small interfering RNA (siRNA)-based therapy led to the development of an effective prophylactic treatment for patients with frequent recurrent attacks. This review will describe treatment options for AHP and highlight management in light of new treatment option. RECENT FINDINGS: Givosiran is a novel siRNA-based therapy targeted specifically to hepatocytes to inhibit ALA synthase 1, the first and rate-limiting step in heme biosynthesis. Patients with frequent recurrent attacks treated with givosiran had durable normalization of ALA and significantly reduced numbers of acute attacks and need for hemin treatment. The overall safety profile for givosiran was comparable with placebo and the drug was recently approved by the Food and Drug Administration for treatment of AHP patients. SUMMARY: Givosiran is an effective treatment for prevention of acute porphyria attacks in AHP patients with frequent recurrent attacks.
Authors: Karl E Anderson; Joseph R Bloomer; Herbert L Bonkovsky; James P Kushner; Claus A Pierach; Neville R Pimstone; Robert J Desnick Journal: Ann Intern Med Date: 2005-03-15 Impact factor: 25.391
Authors: Lei Jiang; Pedro Berraondo; Daniel Jericó; Lin T Guey; Ana Sampedro; Andrea Frassetto; Kerry E Benenato; Kristine Burke; Eva Santamaría; Manuel Alegre; Álvaro Pejenaute; Mayur Kalariya; William Butcher; Ji-Sun Park; Xuling Zhu; Staci Sabnis; E Sathyajith Kumarasinghe; Timothy Salerno; Matthew Kenney; Christine M Lukacs; Matías A Ávila; Paolo G V Martini; Antonio Fontanellas Journal: Nat Med Date: 2018-10-08 Impact factor: 53.440
Authors: Delia D'Avola; Esperanza López-Franco; Bruno Sangro; Astrid Pañeda; Nadina Grossios; Irene Gil-Farina; Alberto Benito; Jaap Twisk; María Paz; Juan Ruiz; Manfred Schmidt; Harald Petry; Pauline Harper; Rafael Enríquez de Salamanca; Antonio Fontanellas; Jesús Prieto; Gloria González-Aseguinolaza Journal: J Hepatol Date: 2016-05-17 Impact factor: 25.083
Authors: Danielle de Brito E Cunha; Ana Beatriz Teixeira Frederico; Tamiris Azamor; Juliana Gil Melgaço; Patricia Cristina da Costa Neves; Ana Paula Dinis Ano Bom; Tatiana Martins Tilli; Sotiris Missailidis Journal: Pharmaceuticals (Basel) Date: 2022-05-05